Physician profile
Jonathan S Berek
NPI 1164447900
$53,884.50
in general payments reported to CMS, 2019-2025
9 companies · $4,040 in 2025
The $4,040 reported for 2025 was more than what 84% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,125 · 2020: $11K · 2021: $6,200 · 2022: $13K · 2023: $11K · 2024: $5,555 · 2025: $4,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Education: $64.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,460.00 |
| Education | $64.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40,245.00 | 2019-2025 | Keytruda, Lynparza |
| Novocure Gmbh | $6,720.00 | 2021-2022 | |
| Novocure INC. | $4,800.00 | 2020 | |
| Eisai INC. | $1,500.00 | 2019 | |
| Astrazeneca Uk Limited | $555.00 | 2022 | |
| Glaxosmithkline, LLC. | $64.50 | 2024 | Zejula |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Berek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.